Mechanism Study of Sulforaphane in ASD Improvement
Key facts
- Who runs it
- Jian-Jun Ou
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 20 Sept 2024
- Ended
- 1 Jul 2026
- Type of study
- Interventional
- Treatments tested
- Sulforaphane
- Record updated
- 4 September 2025
- Why it stopped
- Study terminated prior to full implementation due to logistical and resource-related considerations. Study procedures and feasibility are currently being re-evaluated, and a revised protocol is under development for future implementation.
Who can take part
- Age
- 12 years to 34 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age between 12-34 years
- Diagnosis of Autism Spectrum Disorder (ASD) as per the DSM-V criteria
- Diagnosis of ASD according to the Autism Diagnostic Interview-Revised (ADI-R)
- Diagnosis of ASD based on the Autism Diagnostic Observation Schedule (ADOS)
- Age between 12-34 years
- No diagnosis of any mental disorders
Who cannot take part
- Bipolar disorder f. Currently taking other psychiatric or neurological medications
- Presence of severe physical illnesses or conditions, such as:
- Congenital heart disease
- Thyroid disorders
- Visual or hearing impairments b. Severe neurological diseases with a clear family history or potential risk factors, such as:; a)Traumatic brain injury b) Encephalitis c) Epilepsy d) High fever seizures e) Birth trauma f） Abnormal EEG c. Known or suspected genetic disorders, such as:
- Down syndrome
- Fragile X syndrome d. Diagnosis of other developmental disorders, such as:
- Isolated intellectual disability b) Isolated language development disorder c) Selective mutism e. Diagnosis of other major psychiatric disorders, such as:
- Liver or kidney dysfunction
- Schizophrenia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to find out if sulforaphane (SFN) can improve social skills and behavior in people with Autism Spectrum Disorder (ASD). ASD is a developmental disorder that affects how children and teenagers interact with others. The number of people diagnosed with ASD has been rising, putting a lot of pressure on families and society. The investigators hope this study will lead to new treatments.
Read full original descriptionShow less
The main questions the investigators want to answer are:
Can sulforaphane help improve social communication in people with ASD? How does sulforaphane affect the balance of certain chemicals in the brain?
The investigators will recruit 50 participants aged 12 to 34 diagnosed with ASD and 30 healthy volunteers for comparison. Participants will:
Take 3 capsules of sulforaphane each day for 8 weeks. Complete regular psychological tests, undergo brain scans, and have their brain activity monitored to assess the treatment's effectiveness.
Through this study, the investigators aim to discover the potential benefits of sulforaphane for individuals with ASD and provide new insights for future treatment options.
The group in the trial
- Sulforaphane Intervention Group for Autism Spectrum DisorderTreatment being tested
Treatment: Sulforaphane
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Study on the Mechanisms of Sulforaphane in Improving Autism Spectrum Disorder
- Record updated
- 4 September 2025